Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors

BACKGROUND: Anti-angiogenic therapies such as bevacizumab upregulate hypoxia-inducible factor-1α (HIF-1α), a possible mechanism of drug resistance. Camptothecin analogues, including SN-38, have been shown to reduce the expression and transcriptional activity of HIF-1α in preclinical models. We hypot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Jeong, Woondong, Ryun Park, Sook, Rapisarda, Annamaria, Fer, Nicole, Kinders, Robert J., Chen, Alice, Melillo, Giovanni, Turkbey, Baris, Steinberg, Seth M., Choyke, Peter, Doroshow, James H., Kummar, Shivaani
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7670584/
https://ncbi.nlm.nih.gov/pubmed/24242862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0048-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados